Tag: semaglutide

Novo Signs $2.6B Hengrui Deal, Presents Semaglutide 2 mg Data
News

Novo Signs $2.6B Hengrui Deal, Presents Semaglutide 2 mg Data

Novo Nordisk has licensed HRS-1596, a Phase 1-ready oral GLP-1/GIP dual agonist from Hengrui Pharma, in a deal worth up to $2.6 billion, while new real-world data linked semaglutide 2 mg with a lower risk of major adverse cardiovascular events than switching to tirzepatide

About Us

HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.

Contact: +91 9354115542

HealthXploreIndia @2026. All Rights Reserved.